Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AstraZeneca licenses obesity drug candidate

by Michael McCoy
November 19, 2023 | A version of this story appeared in Volume 101, Issue 38

 

AstraZeneca will pay $185 million up front and up to $1.8 billion in other payments to license a potential obesity and type 2 diabetes treatment from the Shanghai-based firm Eccogene. The compound, ECC5004, is a small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist that can be taken orally. GLP-1 drugs on the market from Novo Nordisk and Eli Lilly and Company are peptides that must be injected. AstraZeneca dropped development of its own oral GLP-1 receptor agonist candidate earlier this year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.